Fig. 2: Simulated concentrations of CAP256V2LS following a single dose (A1, A2) and each 24-week steady state dose (B1, B2) with and without EDP. | Nature Communications

Fig. 2: Simulated concentrations of CAP256V2LS following a single dose (A1, A2) and each 24-week steady state dose (B1, B2) with and without EDP.

From: Hyaluronidase-enhanced subcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical trial in HIV-uninfected women

Fig. 2

In each case, groups with EDP have higher concentrations for equivalent doses, although it occurs in later weeks for the single dose profile. This results in more consistent differences following multiple doses. Solid lines represent median values of 1000 replicates from the model, while the ribbon represents the 95% confidence interval of these replicates. The pharmacokinetic model was based on the results from the complete CAPRISA 012B trial6.

Back to article page